MedTrace Logo

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

NCT00771329 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2013-09-16

No results posted yet for this study

Summary

Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.

Conditions

Interventions

DRUG

BIIB023

Single IV doses of BIIB023 in dose-escalating cohorts

OTHER

Placebo (sterile normal saline)

Single IV dose of Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771329 on ClinicalTrials.gov